Michael Browning

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. pmc Can neuroimaging help us to understand and classify somatoform disorders? A systematic and critical review
    Michael Browning
    Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford OX3 7JX, UK
    Psychosom Med 73:173-84. 2011
  2. pmc Using attentional bias modification as a cognitive vaccine against depression
    Michael Browning
    Department of Psychiatry, University of Oxford, Oxford, United Kingdom
    Biol Psychiatry 72:572-9. 2012
  3. pmc Using an experimental medicine model to explore combination effects of pharmacological and cognitive interventions for depression and anxiety
    Michael Browning
    Department of Psychiatry, University of Oxford, Oxford, UK
    Neuropsychopharmacology 36:2689-97. 2011
  4. pmc Lateral prefrontal cortex mediates the cognitive modification of attentional bias
    Michael Browning
    Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom
    Biol Psychiatry 67:919-25. 2010
  5. doi request reprint The modification of attentional bias to emotional information: A review of the techniques, mechanisms, and relevance to emotional disorders
    Michael Browning
    Department of Psychiatry, University of Oxford, Oxford, England
    Cogn Affect Behav Neurosci 10:8-20. 2010
  6. pmc Expectancy and surprise predict neural and behavioral measures of attention to threatening stimuli
    Michael Browning
    Department of Psychiatry, Oxford University, Oxford, UK
    Neuroimage 59:1942-8. 2012
  7. doi request reprint Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing
    Jamie Horder
    University Department of Psychiatry, Neurosciences Building, Warneford Hospital, Oxford, UK
    J Psychopharmacol 26:125-32. 2012
  8. doi request reprint The use of cognitive bias modification and imagery in the understanding and treatment of depression
    Michael Browning
    Department of Psychiatry, University of Oxford, UK
    Curr Top Behav Neurosci 14:243-60. 2013
  9. doi request reprint Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers
    Jamie Horder
    University Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK
    Psychopharmacology (Berl) 205:85-91. 2009

Detail Information

Publications9

  1. pmc Can neuroimaging help us to understand and classify somatoform disorders? A systematic and critical review
    Michael Browning
    Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford OX3 7JX, UK
    Psychosom Med 73:173-84. 2011
    ..two specific questions: Is there evidence of altered neural function or structure that is specifically associated with somatoform disorders? What conclusions can we draw from these findings about the etiology of somatoform disorders?..
  2. pmc Using attentional bias modification as a cognitive vaccine against depression
    Michael Browning
    Department of Psychiatry, University of Oxford, Oxford, United Kingdom
    Biol Psychiatry 72:572-9. 2012
    ....
  3. pmc Using an experimental medicine model to explore combination effects of pharmacological and cognitive interventions for depression and anxiety
    Michael Browning
    Department of Psychiatry, University of Oxford, Oxford, UK
    Neuropsychopharmacology 36:2689-97. 2011
    ..More generally, the findings suggest that pinpointing the cognitive actions of treatments may inform future development of combination strategies in mental health...
  4. pmc Lateral prefrontal cortex mediates the cognitive modification of attentional bias
    Michael Browning
    Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom
    Biol Psychiatry 67:919-25. 2010
    ..It has been hypothesized, but not proved, that psychological interventions may alter the function of prefrontal regions supervising the allocation of attentional resources...
  5. doi request reprint The modification of attentional bias to emotional information: A review of the techniques, mechanisms, and relevance to emotional disorders
    Michael Browning
    Department of Psychiatry, University of Oxford, Oxford, England
    Cogn Affect Behav Neurosci 10:8-20. 2010
    ..Finally, we suggest a conceptual framework that embraces both pharmacological and psychological approaches and consider the possible implications of this work for future research and treatment development...
  6. pmc Expectancy and surprise predict neural and behavioral measures of attention to threatening stimuli
    Michael Browning
    Department of Psychiatry, Oxford University, Oxford, UK
    Neuroimage 59:1942-8. 2012
    ..These results suggest that continuously calculated estimates of the probability of threat may plausibly be used to influence the deployment of visual attention and that use of this information is perturbed in anxious individuals...
  7. doi request reprint Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing
    Jamie Horder
    University Department of Psychiatry, Neurosciences Building, Warneford Hospital, Oxford, UK
    J Psychopharmacol 26:125-32. 2012
    ..Investigating such effects could be useful in detecting adverse psychiatric effects of novel treatments...
  8. doi request reprint The use of cognitive bias modification and imagery in the understanding and treatment of depression
    Michael Browning
    Department of Psychiatry, University of Oxford, UK
    Curr Top Behav Neurosci 14:243-60. 2013
    ..In summary, by providing a method for altering habitual cognitive function in experimental and clinical settings CBM techniques have begun to further the understanding of and the treatment for depression...
  9. doi request reprint Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers
    Jamie Horder
    University Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK
    Psychopharmacology (Berl) 205:85-91. 2009
    ..The anti-obesity drug and cannabinoid type 1 receptor antagonist, rimonabant, is associated with significant rates of depression and anxiety in clinical use...